These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 30255250)

  • 1. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK
    Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
    Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
    Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma.
    Li Y; Chen J; Weng S; Yan C; Ye R; Zhu Y; Wen L; Cao D; Hong J
    Ann Transl Med; 2021 Jan; 9(1):55. PubMed ID: 33553348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK; Choi BI
    Eur Radiol; 2015 Oct; 25(10):2859-68. PubMed ID: 25773941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
    Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
    Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable?
    Lim K; Kwon H; Cho J; Kim D; Kang E; Kim S
    Br J Radiol; 2022 Apr; 95(1132):20210738. PubMed ID: 34928175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
    Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK
    Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 11. Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases.
    Kim DH; Choi SH; Kim SY; Kim MJ; Lee SS; Byun JH
    Radiology; 2019 Jun; 291(3):651-657. PubMed ID: 30990381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
    Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
    AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
    [No Abstract]   [Full Text] [Related]  

  • 13. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
    Kang HJ; Lee JM; Yoon JH; Han JK
    Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?
    Baek KA; Kim SS; Shin HC; Hwang JA; Choi SY; Lee WH; Park CH; Lee HN; Heo NH
    Abdom Radiol (NY); 2020 Sep; 45(9):2705-2716. PubMed ID: 32382820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.
    Pan J; Tao Y; Chi X; Yang L; Zhao Y; Chen F
    Eur Radiol; 2022 Aug; 32(8):5134-5143. PubMed ID: 35267090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.